{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-008665","form_type":"8-K","ticker":"STIM","cik":"0001227636","company_name":"Neuronetics, Inc.","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.194003+00:00","generated_at":"2026-06-15T08:18:14.137559+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Neuronetics Q1 revenue $15.5M (+10% YoY); narrows FY revenue guidance to $68-73M","bullets":["Net loss of $(10.5)M or $(0.38)/share vs $(10.8)M or $(0.41)/share in Q1 2022.","U.S. treatment session revenue rose 12% to $10.6M; shipped 49 NeuroStar systems.","Full-year 2023 revenue guidance set at $68-73M; Q2 2023 revenue expected $17-18M.","Amended SLR credit facility provides up to $60M at SOFR+5.65%, interest-only until March 2026.","United Healthcare and BCBS of Mississippi updated policies to allow NPPs to prescribe TMS."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-008665","json":"https://secwatch.observer/filing/0001558370-23-008665.json","markdown":"https://secwatch.observer/filing/0001558370-23-008665.md","text":"https://secwatch.observer/filing/0001558370-23-008665.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1227636/000155837023008665/0001558370-23-008665-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1227636/000155837023008665/stim-20230509x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T08:18:14.137559+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"446688e9d33f278dc43708036088297997bec92b","claim":"Neuronetics, Inc. reported the three months ended March 31, 2023 results: revenue $15.5 million, net income $(10.5) million, EPS $(0.38) per share.","evidence_excerpt":"therapies in the world, today announced its financial and operating results for the first quarter of 2023. First Quarter 2023 Highlights ● First quarter 2023 revenue of $15.5 million, an increase of 10% over the first quarter of 2022 ● U.S. treatment session revenue increased 12% over the first quarter of 2022 ● Shipped 49 systems continuing our capital","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1227636/000155837023008665/0001558370-23-008665-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2023"},{"label":"Revenue","value":"$15.5 million"},{"label":"Net income","value":"$(10.5) million"},{"label":"EPS","value":"$(0.38) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}